Abstract
The alternative approaches for antibacterial drug discovery have a huge potential to develop novel antibacterial agents against multi drug resistant human pathogenic bacteria that are much needed to tackle the urgent threats of multi drug resistant human pathogenic bacteria. We may be able to develop much faster novel antibiotics against multi drug resistant human pathogenic bacteria using these alternative methods than that based on small molecule drug discovery. The alternative methods for antibacterial drug discovery can be used to target new molecules in pathogenic bacteria such as bacterial riboswitches. The combination of novel mechanisms of antibacterial drug action, with novel molecules targets, can result in the development of novel antibiotics against which bacteria have yet not developed any kind of resistance.
In this book chapter, we present novel methods for antibacterial drug discovery against antimicrobial resistant bacteria based on alternative strategies for antibacterial drug discovery. These include the application of antisense oligonucleotides as antibacterial agents, fecal microbiota transplantation, and antimicrobial peptides and cell penetrating peptides with antibacterial activity. We also present the main ways of antibiotics misuse that lead to the development of antimicrobial resistance.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Akdag I, Ozkirimli E (2013) The uptake mechanism of the cell-penetrating pVEC peptide. J Chem 2013:1–9. https://doi.org/10.1155/2013/851915
Alaybeyoglu B, SariyarAkbulut B, Ozkirimli E (2018) pVEC hydrophobic N-terminus is critical for antibacterial activity. J Pept Sci 24(6):e3083. https://doi.org/10.1002/psc.3083
Allcock S, Young EH, Holmes M, Gurdasani D, Dougan G, Sandhu MS et al (2017) Antimicrobial resistance in human populations: challenges and opportunities. Glob Health Epidemiol Genom 2:e4. https://doi.org/10.1017/gheg.2017.4
Barlam TF, Cosgrove SE, Abbo LM, MacDougall C, Schuetz AN, Septimus EJ et al (2016) Implementing an Antibiotic Stewardship Program: guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America. Clin Infect Dis 62(10):e51–e77. https://doi.org/10.1093/cid/ciw118
Bassetti M, Poulakou G, Ruppe E, Bouza E, Van Hal SJ, Brink A (2017) Antimicrobial resistance in the next 30 years, humankind, bugs and drugs: a visionary approach. Intensive Care Med 43(10):1464–1475. https://doi.org/10.1007/s00134-017-4878-x
Benincasa M, Pacor S, Gennaro R, Scocchi M (2009) Rapid and reliable detection of antimicrobial peptide penetration into gram-negative bacteria based on fluorescence quenching. Antimicrob Agents Chemother 53(8):3501–3504. https://doi.org/10.1128/AAC.01620-08
Bennadi D (2013) Self-medication: a current challenge. J Basic Clin Pharm 5(1):19–23. https://doi.org/10.4103/0976-0105.128253
Blair JM, Webber MA, Baylay AJ, Ogbolu DO, Piddock LJ (2015) Molecular mechanisms of antibiotic resistance. Nat Rev Microbiol 13(1):42–51. https://doi.org/10.1038/nrmicro3380
Boparai JK, Sharma PK (2019) Mini review on antimicrobial peptides, sources, mechanism and recent applications. Protein Pept Lett 27:4–16. https://doi.org/10.2174/0929866526666190822165812
Borysowski J, Gorski A (2008) Is phage therapy acceptable in the immunocompromised host? Int J Infect Dis 12(5):466–471. https://doi.org/10.1016/j.ijid.2008.01.006
Capitanio D, Moriggi M, Torretta E, Barbacini P, De Palma S, Vigano A et al (2020) Comparative proteomic analyses of Duchenne muscular dystrophy and Becker muscular dystrophy muscles: changes contributing to preserve muscle function in Becker muscular dystrophy patients. J Cachexia Sarcopenia Muscle 11:547–563. https://doi.org/10.1002/jcsm.12527
Chan JH, Lim S, Wong WS (2006) Antisense oligonucleotides: from design to therapeutic application. Clin Exp Pharmacol Physiol 33(5–6):533–540. https://doi.org/10.1111/j.1440-1681.2006.04403.x
Cho I, Blaser MJ (2012) The human microbiome: at the interface of health and disease. Nat Rev Genet 13(4):260–270. https://doi.org/10.1038/nrg3182
Cociancich S, Dupont A, Hegy G, Lanot R, Holder F, Hetru C et al (1994) Novel inducible antibacterial peptides from a hemipteran insect, the sap-sucking bug Pyrrhocorisapterus. Biochem J 300(Pt 2):567–575. https://doi.org/10.1042/bj3000567
de With K, Allerberger F, Amann S, Apfalter P, Brodt HR, Eckmanns T et al (2016) Strategies to enhance rational use of antibiotics in hospital: a guideline by the German Society for Infectious Diseases. Infection 44(3):395–439. https://doi.org/10.1007/s15010-016-0885-z
Dellit TH, Owens RC, McGowan JE Jr, Gerding DN, Weinstein RA, Burke JP et al (2007) Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis 44(2):159–177. https://doi.org/10.1086/510393
Dik JW, Poelman R, Friedrich AW, Panday PN, Lo-Ten-Foe JR, van Assen S et al (2016) An integrated stewardship model: antimicrobial, infection prevention and diagnostic (AID). Future Microbiol 11(1):93–102. https://doi.org/10.2217/fmb.15.99
Domingo-Calap P, Georgel P, Bahram S (2016) Back to the future: bacteriophages as promising therapeutic tools. HLA 87(3):133–140. https://doi.org/10.1111/tan.12742
Duckworth DH (1976) Who discovered bacteriophage? Bacteriol Rev 40(4):793–802
Durzynska J, Przysiecka L, Nawrot R, Barylski J, Nowicki G, Warowicka A et al (2015) Viral and other cell-penetrating peptides as vectors of therapeutic agents in medicine. J Pharmacol Exp Ther 354(1):32–42. https://doi.org/10.1124/jpet.115.223305
Fair RJ, Tor Y (2014) Antibiotics and bacterial resistance in the 21st century. Perspect Med Chem 6:25–64. https://doi.org/10.4137/PMC.S14459
Fensterseifer ICM, Felicio MR, Alves ESF, Cardoso MH, Torres MDT, Matos CO et al (2019) Selective antibacterial activity of the cationic peptide PaDBS1R6 against Gram-negative bacteria. Biochim Biophys Acta Biomembr 1861(7):1375–1387. https://doi.org/10.1016/j.bbamem.2019.03.016
Fischetti VA (2005) Bacteriophage lytic enzymes: novel anti-infectives. Trends Microbiol 13(10):491–496. https://doi.org/10.1016/j.tim.2005.08.007
Fishman N (2006). Antimicrobial stewardship. Am J Med 119(6 Suppl 1):S53–S61; discussion S62-70. https://doi.org/10.1016/j.amjmed.2006.04.003
Garau J, Nicolau DP, Wullt B, Bassetti M (2014) Antibiotic stewardship challenges in the management of community-acquired infections for prevention of escalating antibiotic resistance. J Glob Antimicrob Resist 2(4):245–253. https://doi.org/10.1016/j.jgar.2014.08.002
Geary RS (2009) Antisense oligonucleotide pharmacokinetics and metabolism. Expert Opin Drug Metab Toxicol 5(4):381–391. https://doi.org/10.1517/17425250902877680
Gleave ME, Monia BP (2005) Antisense therapy for cancer. Nat Rev Cancer 5(6):468–479. https://doi.org/10.1038/nrc1631
Goodridge LD (2010) Designing phage therapeutics. Curr Pharm Biotechnol 11(1):15–27
Hayes JD, Wolf CR (1990) Molecular mechanisms of drug resistance. Biochem J 272(2):281–295. https://doi.org/10.1042/bj2720281
Hollister EB, Gao C, Versalovic J (2014) Compositional and functional features of the gastrointestinal microbiome and their effects on human health. Gastroenterology 146(6):1449–1458. https://doi.org/10.1053/j.gastro.2014.01.052
Jonczyk-Matysiak E, Lodej N, Kula D, Owczarek B, Orwat F, Miedzybrodzki R et al (2019) Factors determining phage stability/activity: challenges in practical phage application. Expert Rev Anti-Infect Ther 17:1–24. https://doi.org/10.1080/14787210.2019.1646126
Kaloudas D, Pavlova N, Penchovsky R (2018) EBWS: Essential bioinformatics Web services for sequence analyses. IEEE/ACM transactions on computational biology and bioinformatics 16(3):942–953. https://doi.org/10.1109/TCBB.2018.2816645
Kauffman WB, Fuselier T, He J, Wimley WC (2015) Mechanism matters: a taxonomy of cell penetrating peptides. Trends Biochem Sci 40(12):749–764. https://doi.org/10.1016/j.tibs.2015.10.004
Khoruts A, Dicksved J, Jansson JK, Sadowsky MJ (2010) Changes in the composition of the human fecal microbiome after bacteriotherapy for recurrent Clostridium difficile-associated diarrhea. J Clin Gastroenterol 44(5):354–360. https://doi.org/10.1097/MCG.0b013e3181c87e02
Kolb SJ, Kissel JT (2011) Spinal muscular atrophy: a timely review. Arch Neurol 68(8):979–984. https://doi.org/10.1001/archneurol.2011.74
Kolb SJ, Kissel JT (2015) Spinal muscular atrophy. Neurol Clin 33(4):831–846. https://doi.org/10.1016/j.ncl.2015.07.004
Kurreck J (2003) Antisense technologies. Improvement through novel chemical modifications. Eur J Biochem 270(8):1628–1644. https://doi.org/10.1046/j.1432-1033.2003.03555.x
Langdon A, Crook N, Dantas G (2016) The effects of antibiotics on the microbiome throughout development and alternative approaches for therapeutic modulation. Genome Med 8(1):39. https://doi.org/10.1186/s13073-016-0294-z
Langel U (2019) Classes and applications of cell-penetrating peptides. In: CPP, cell-penetrating peptides. Springer, Singapore, pp 61–63
Le CF, Fang CM, Sekaran SD (2017) Intracellular targeting mechanisms by antimicrobial peptides. Antimicrob Agents Chemother 61(4). https://doi.org/10.1128/AAC.02340-16
Lehman SM, Donlan RM (2015) Bacteriophage-mediated control of a two-species biofilm formed by microorganisms causing catheter-associated urinary tract infections in an in vitro urinary catheter model. Antimicrob Agents Chemother 59(2):1127–1137. https://doi.org/10.1128/AAC.03786-14
Levy SB, Marshall B (2004) Antibacterial resistance worldwide: causes, challenges and responses. Nat Med 10(12 Suppl):S122–S129. https://doi.org/10.1038/nm1145
Lindblad W (2008) Considerations for Determining if a Natural Product Is an Effective Wound-Healing Agent. The International Journal of Lower Extremity Wounds 7(2):75–81. https://doi.org/10.1177/1534734608316028
Lv M, Duan B, Lu K, Wu Y, Zhao Y (2017) Synthesis, DNA-binding and antibacterial activity of the cell-penetrating peptide HIV-1 tat (49-57). Indian J Pharm Sci 79. https://doi.org/10.4172/pharmaceutical-sciences.1000305
Malik S, Sidhu PK, Rana JS, Nehra K (2019) Managing urinary tract infections through phage therapy: a novel approach. Folia Microbiol (Praha) 65:217–231. https://doi.org/10.1007/s12223-019-00750-y
Mantravadi PK, Kalesh KA, Dobson RCJ, Hudson AO, Parthasarathy A (2019) The quest for novel antimicrobial compounds: emerging trends in research, development, and technologies. Antibiotics (Basel) 8(1). https://doi.org/10.3390/antibiotics8010008
Mardirossian M, Grzela R, Giglione C, Meinnel T, Gennaro R, Mergaert P, Scocchi M (2014) The host antimicrobial peptide Bac71-35 binds to bacterial ribosomal proteins and inhibits protein synthesis. Chem Biol 21(12):1639–1647. https://doi.org/10.1016/j.chembiol.2014.10.009
Mayers D, Sobel J, Ouellette M, Kaye K, Marchaim D (2017) Antimicrobial drug resistance: mechanisms of drug resistance, volume 1. Springer-Verlag, Berlin Heidelberg
McPhee JB, Tamber S, Brazas MD, Lewenza S, Hancock REW (2009) Antibiotic resistance due to reduced uptake, pp 97–110. https://doi.org/10.1007/978-1-59745-180-2_9
Meng J, Da F, Ma X, Wang N, Wang Y, Zhang H et al (2015) Antisense growth inhibition of methicillin-resistant Staphylococcus aureus by locked nucleic acid conjugated with cell-penetrating peptide as a novel FtsZ inhibitor. Antimicrob Agents Chemother 59(2):914–922. https://doi.org/10.1128/AAC.03781-14
Meyers S, Shih J, Neher JO, Safranek S (2018) Clinical inquiries: how effective and safe is fecal microbial transplant in preventing C difficile recurrence? J Fam Pract 67(6):386–388
Moller-Olsen C, Ho SFS, Shukla RD, Feher T, Sagona AP (2018) Engineered K1F bacteriophages kill intracellular Escherichia coli K1 in human epithelial cells. Sci Rep 8(1):17559. https://doi.org/10.1038/s41598-018-35859-6
Mullish BH, Quraishi MN, Segal JP, McCune VL, Baxter M, Marsden GL et al (2018) The use of faecal microbiota transplant as treatment for recurrent or refractory Clostridium difficile infection and other potential indications: joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines. Gut 67(11):1920–1941. https://doi.org/10.1136/gutjnl-2018-316818
Munita JM, Arias CA (2016) Mechanisms of antibiotic resistance. Microbiol Spectrosc 4(2). https://doi.org/10.1128/microbiolspec.VMBF-0016-2015
Nakase I, Akita H, Kogure K, Graslund A, Langel U, Harashima H, Futaki S (2012) Efficient intracellular delivery of nucleic acid pharmaceuticals using cell-penetrating peptides. Acc Chem Res 45(7):1132–1139. https://doi.org/10.1021/ar200256e
Nan YH, Park IS, Hahm KS, Shin SY (2011) Antimicrobial activity, bactericidal mechanism and LPS-neutralizing activity of the cell-penetrating peptide pVEC and its analogs. J Pept Sci 17(12):812–817. https://doi.org/10.1002/psc.1408
Narayanan S, Modak JK, Ryan CS, Garcia-Bustos J, Davies JK, Roujeinikova A (2014) Mechanism of Escherichia coli resistance to Pyrrhocoricin. Antimicrob Agents Chemother 58(5):2754–2762. https://doi.org/10.1128/AAC.02565-13
Okeke IN, Klugman KP, Bhutta ZA, Duse AG, Jenkins P, O’Brien TF et al (2005) Antimicrobial resistance in developing countries. Part II: strategies for containment. Lancet Infect Dis 5(9):568–580. https://doi.org/10.1016/S1473-3099(05)70217-6
Paik J, Duggan S (2019) Volanesorsen: first global approval. Drugs 79:1349–1354. https://doi.org/10.1007/s40265-019-01168-z
Palm C, Netzereab S, Hallbrink M (2006) Quantitatively determined uptake of cell-penetrating peptides in non-mammalian cells with an evaluation of degradation and antimicrobial effects. Peptides 27(7):1710–1716. https://doi.org/10.1016/j.peptides.2006.01.006
Pane M, Palermo C, Messina S, Sansone VA, Bruno C, Catteruccia M et al (2018) Nusinersen in type 1 SMA infants, children and young adults: preliminary results on motor function. Neuromuscul Disord 28(7):582–585. https://doi.org/10.1016/j.nmd.2018.05.010
Pavlova N, Penchovsky R (2019) Genome-wide bioinformatics analysis of FMN, SAM-I, glmS, TPP, lysine, purine, cobalamin, and SAH riboswitches for their applications as allosteric antibacterial drug targets in human pathogenic bacteria. Expert opinion on therapeutic targets 23(7):631–643. https://doi.org/10.1080/14728222.2019.1618274
Pelfrene E, Willebrand E, Cavaleiro Sanches A, Sebris Z, Cavaleri M (2016) Bacteriophage therapy: a regulatory perspective. J Antimicrob Chemother 71(8):2071–2074. https://doi.org/10.1093/jac/dkw083
Pena C, Pujol M, Ricart A, Ardanuy C, Ayats J, Linares J et al (1997) Risk factors for faecal carriage of Klebsiella pneumoniae producing extended spectrum beta-lactamase (ESBL-KP) in the intensive care unit. J Hosp Infect 35(1):9–16
Penchovsky R, Traykovska M (2015) Designing drugs that overcome antibacterial resistance: where do we stand and what should we do? Expert Opin Drug Discov 10(6):631–650. https://doi.org/10.1517/17460441.2015.1048219
Pfalzgraff A, Brandenburg K, Weindl G (2018) Antimicrobial peptides and their therapeutic potential for bacterial skin infections and wounds. Front Pharmacol 9:281. https://doi.org/10.3389/fphar.2018.00281
Reiner Z (2018) Triglyceride-rich lipoproteins and novel targets for anti-atherosclerotic therapy. Korean Circ J 48(12):1097–1119. https://doi.org/10.4070/kcj.2018.0343
Rinaldi C, Wood MJA (2018) Antisense oligonucleotides: the next frontier for treatment of neurological disorders. Nat Rev Neurol 14(1):9–21. https://doi.org/10.1038/nrneurol.2017.148
Rodriguez Plaza JG, Morales-Nava R, Diener C, Schreiber G, Gonzalez ZD, Lara Ortiz MT et al (2014) Cell penetrating peptides and cationic antibacterial peptides: two sides of the same coin. J Biol Chem 289(21):14448–14457. https://doi.org/10.1074/jbc.M113.515023
Rodriguez L, Martinez B, Zhou Y, Rodriguez A, Donovan DM, Garcia P (2011) Lytic activity of the virion-associated peptidoglycan hydrolase HydH5 of Staphylococcus aureus bacteriophage vB_SauS-phiIPLA88. BMC Microbiol 11:138. https://doi.org/10.1186/1471-2180-11-138
Rodriguez-Mozaz S, Chamorro S, Marti E, Huerta B, Gros M, Sanchez-Melsio A et al (2015) Occurrence of antibiotics and antibiotic resistance genes in hospital and urban wastewaters and their impact on the receiving river. Water Res 69:234–242. https://doi.org/10.1016/j.watres.2014.11.021
Runti G, Benincasa M, Giuffrida G, Devescovi G, Venturi V, Gennaro R, Scocchi M (2017) The mechanism of killing by the proline-rich peptide Bac7(1-35) against clinical strains of Pseudomonas aeruginosa differs from that against other Gram-negative bacteria. Antimicrob Agents Chemother 61(4). https://doi.org/10.1128/AAC.01660-16
Scocchi M, Tossi A, Gennaro R (2011) Proline-rich antimicrobial peptides: converging to a non-lytic mechanism of action. Cell Mol Life Sci 68(13):2317–2330. https://doi.org/10.1007/s00018-011-0721-7
Seil M, Nagant C, Dehaye JP, Vandenbranden M, Lensink MF (2010) Spotlight on human LL-37, an immunomodulatory peptide with promising cell-penetrating properties. Pharmaceuticals 3(11):3435–3460. https://doi.org/10.3390/ph3113435
Selgelid MJ (2007) Ethics and drug resistance. Bioethics 21(4):218–229. https://doi.org/10.1111/j.1467-8519.2006.00542.x
Septimus EJ (2018) Antimicrobial resistance: an antimicrobial/diagnostic stewardship and infection prevention approach. Med Clin North Am 102(5):819–829. https://doi.org/10.1016/j.mcna.2018.04.005
Seth PP, Tanowitz M, Bennett CF (2019) Selective tissue targeting of synthetic nucleic acid drugs. J Clin Invest 129(3):915–925. https://doi.org/10.1172/JCI125228
Sharma S, Chatterjee S, Datta S, Prasad R, Dubey D, Prasad RK, Vairale MG (2017) Bacteriophages and its applications: an overview. Folia Microbiol (Praha) 62(1):17–55. https://doi.org/10.1007/s12223-016-0471-x
Shasmal M, Sengupta J (2012) Structural diversity in bacterial ribosomes: mycobacterial 70S ribosome structure reveals novel features. PLoS One 7(2):e31742. https://doi.org/10.1371/journal.pone.0031742
Shogbesan O, Poudel DR, Victor S, Jehangir A, Fadahunsi O, Shogbesan G, Donato A (2018) A systematic review of the efficacy and safety of fecal microbiota transplant for Clostridium difficile infection in immunocompromised patients. Can J Gastroenterol Hepatol 2018:1394379–1394310. https://doi.org/10.1155/2018/1394379
Singh SB, Phillips JW, Wang J (2007) Highly sensitive target-based whole-cell antibacterial discovery strategy by antisense RNA silencing. Curr Opin Drug Discov Devel 10(2):160–166
Smith PA, Romesberg FE (2007) Combating bacteria and drug resistance by inhibiting mechanisms of persistence and adaptation. Nat Chem Biol 3(9):549–556. https://doi.org/10.1038/nchembio.2007.27
Soothill G, Hu Y, Coates A (2013) Can we prevent antimicrobial resistance by using antimicrobials better? Pathogens 2(2):422–435. https://doi.org/10.3390/pathogens2020422
Splith K, Neundorf I (2011) Antimicrobial peptides with cell-penetrating peptide properties and vice versa. Eur Biophys J 40(4):387–397. https://doi.org/10.1007/s00249-011-0682-7
Stein CA, Castanotto D (2017) FDA-approved oligonucleotide therapies in 2017. Mol Ther 25(5):1069–1075. https://doi.org/10.1016/j.ymthe.2017.03.023
Sully EK, Geller BL (2016) Antisense antimicrobial therapeutics. Curr Opin Microbiol 33:47–55. https://doi.org/10.1016/j.mib.2016.05.017
Tang SS, Apisarnthanarak A, Hsu LY (2014) Mechanisms of beta-lactam antimicrobial resistance and epidemiology of major community- and healthcare-associated multidrug-resistant bacteria. Adv Drug Deliv Rev 78:3–13. https://doi.org/10.1016/j.addr.2014.08.003
Taniguchi M, Ochiai A, Kondo H, Fukuda S, Ishiyama Y, Saitoh E et al (2016) Pyrrhocoricin, a proline-rich antimicrobial peptide derived from insect, inhibits the translation process in the cell-free Escherichia coli protein synthesis system. J Biosci Bioeng 121(5):591–598. https://doi.org/10.1016/j.jbiosc.2015.09.002
Tenover FC (2006) Mechanisms of antimicrobial resistance in bacteria. Am J Med 119(6 Suppl 1):S3–S10; discussion S62–S70. https://doi.org/10.1016/j.amjmed.2006.03.011
Traykovska M, Miedema S, Penchovsky R (2018) Clinical Trials of Functional Nucleic Acids: Antisense Oligonucleotides and Aptamers. International Journal of Biomedical and Clinical Engineering (IJBCE) 7(2):46–60. https://doi.org/10.4018/IJBCE.2018070104
Tsoumpra MK, Fukumoto S, Matsumoto T, Takeda S, Wood MJA, Aoki Y (2019) Peptide-conjugate antisense based splice-correction for Duchenne muscular dystrophy and other neuromuscular diseases. EBioMedicine 45:630–645. https://doi.org/10.1016/j.ebiom.2019.06.036
Vellar ID (2002) Thomas B Hugh, Howard Florey, Alexander Fleming and the fairy tale of penicillin. Medical Journal of Australia 176(4):178–180. https://doi.org/10.5694/j.1326-5377.2002.tb04641.x
Verraes C, Van Boxstael S, Van Meervenne E, Van Coillie E, Butaye P, Catry B et al (2013) Antimicrobial resistance in the food chain: a review. Int J Environ Res Public Health 10(7):2643–2669. https://doi.org/10.3390/ijerph10072643
Waksman SA (1973) Selman Abraham Waksman, Ph.D. 22 July 1888-16 August 1973. Who “discovered” streptomycin? Annals of Internal Medicine 79(5):646
Waksman SA, Flynn JE (1973) History of the word `antibiotic. Journal of the History of Medicine and Allied Sciences 28(3):284–286. https://doi.org/10.1093/jhmas/XXVIII.3.284
Wang Z, Wang X, Wang J (2018) Recent advances in antibacterial and antiendotoxic peptides or proteins from marine resources. Mar Drugs 16(2). https://doi.org/10.3390/md16020057
Wei L, Gao J, Zhang S, Wu S, Xie Z, Ling G et al (2015) Identification and characterization of the first cathelicidin from sea snakes with potent antimicrobial and anti-inflammatory activity and special mechanism. J Biol Chem 290(27):16633–16652. https://doi.org/10.1074/jbc.M115.642645
WHO (2002) The selection and use of essential medicines. Report of the WHO expert commitee. WHO, Geneva
WHO (2015) WHO model list of essential medicines. WHO, Geneva
Wilson BC, Vatanen T, Cutfield WS, O’Sullivan JM (2019) The super-donor phenomenon in fecal microbiota transplantation. Front Cell Infect Microbiol 9:2. https://doi.org/10.3389/fcimb.2019.00002
Wright GD (2009) Making sense of antisense in antibiotic drug discovery. Cell Host Microbe 6(3):197–198. https://doi.org/10.1016/j.chom.2009.08.009
Yiu EM, Kornberg AJ (2015) Duchenne muscular dystrophy. J Paediatr Child Health 51(8):759–764. https://doi.org/10.1111/jpc.12868
Yoon MY, Yoon SS (2018) Disruption of the gut ecosystem by antibiotics. Yonsei Med J 59(1):4–12. https://doi.org/10.3349/ymj.2018.59.1.4
Zhu WL, Lan H, Park IS, Kim JI, Jin HZ, Hahm KS, Shin SY (2006) Design and mechanism of action of a novel bacteria-selective antimicrobial peptide from the cell-penetrating peptide Pep-1. Biochem Biophys Res Commun 349(2):769–774. https://doi.org/10.1016/j.bbrc.2006.08.094
Acknowledgments
This work was financed by a grant DN/13/14/20.12.2017 awarded by the Bulgarian National Science Fund (BNSF).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Valsamatzi-Panagiotou, A., Popova, K.B., Penchovsky, R. (2020). Drug Discovery for Targeting Drug Resistant Bacteria. In: Panwar, H., Sharma, C., Lichtfouse, E. (eds) Sustainable Agriculture Reviews 46. Sustainable Agriculture Reviews, vol 46. Springer, Cham. https://doi.org/10.1007/978-3-030-53024-2_9
Download citation
DOI: https://doi.org/10.1007/978-3-030-53024-2_9
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-53023-5
Online ISBN: 978-3-030-53024-2
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)